Industrial, scientific and engineering operations are critically dependent on the precise measurement of basic physical parameters. Among the best known manufacturers of many of the devices required for these purposes is headquartered in Santa Clara, California.
Agilent Technologies (NYSE: A) provides electronic measurement and bio-analytical solutions to the communications, electronics, life sciences and chemical analysis industries. Its Electronic Measurement segment offers such instruments as data generators, multimeters, and oscilloscopes. Its Bio-Analytical Measurement segment provides instruments and consumables that enable customers to quantify the biological properties of substances. Customers include Cisco Systems (NASDAQ: CSCO), Dow Chemical (NYSE: DOW), Intel (NASDAQ: INTC) and Merck (NYSE: MRK). The firm was a 1999 spin-off of Hewlett-Packard (NYSE: HPQ).
Agilent announced the acquisition of life science research and diagnostic products firm Stratagene last week and said
that, as a result, it expects Q3 revenues to be in the range $1.38-$1.42 billion. Analysts had been looking for $1.38 billion. The acquisition did not affect the company's earnings outlook. The news kept Agilent shares cycling through a positive two-month trading channel. The price is currently consolidating at the base of that channel, where oversold CCI, MACD, Momentum, RSI and Stochastic technical parameters suggest the potential for a rise back toward the top. Correspondence of the stock's 30-day moving average curve to the base of the channel backs the rebound notion.
Brokers recommend the issue with two "strong buys," three "buys" and four "holds." Analysts expect a 19% growth rate through the next year. The Agilent Price to Free Cash Flow ratio (21.92), Operating Margin (11.09%), Net Profit Margin (12.48%), Return on Assets (7.82%) and Return on Investment (10.00%) compare favorably with industry averages.
Institutional investors hold about 74% of the outstanding shares. The stock is one of those used to calculate the S&P 500 Index. Over the past 52 weeks, it has traded between $26.96 and $38.97. A stop-loss of $32.70 looks good here. Note that the firm expects to report Q3 results in mid-August.
Larry Schutts is a contributing editor for Theflyonthewall.com and the Vice-President of Stockwinners.com.